- Behavioral Health and Gastro Intestinal conditions
- Rare Diseases
- Regenerative Medicine
Shire's success in phase 3 trials of Lanadelumab may mean it has also found a cure for a damaged track record in M&A.
Markets shrugged off weak industrial data from China to focus on economics and earnings news closer to home